Colorectal Cancer – Landscape & Forecast – Disease Landscape & Forecast

Chemotherapy remains the dominant cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. Patient biomarker status (e.g., BRAF, RAS, MSI-H/dMMR) and tumor location play a key role in guiding treatment selection. Immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo) and BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi) have recently emerged as novel options and will see robust uptake in eligible patients. Further personalization of treatment will ensure continued uptake of currently approved therapies over the 2020-2030 forecast period. We also expect several novel agents and combinations to impact the market and help address the high unmet need for additional and more-efficacious treatments.

QUESTIONS ANSWERED

  • How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?
  • What are key opinion leaders’ views on current and emerging therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?
  • Which pipeline products are poised to launch for colorectal cancer, and what unmet needs do they address?
  • What are the key drivers and constraints on the colorectal cancer therapy market, and how will the major markets evolve over the 10-year forecast period?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q3 2021
        • October 2021
        • September 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
    • Key Findings
      • Colorectal Cancer u2013 Key Findings
        • December 2020
    • Market Outlook
      • Key Findings
        • Market Share of Drug Classes for Colorectal Cancer: 2020
        • Market Share of Drug Classes for Colorectal Cancer: 2030
        • Drug-Treatable Population Share and Major-Market Sales Share in Colorectal Cancer: 2020
        • Drug-Treatable Population Share and Major-Market Sales Share in Colorectal Cancer: 2030
        • Population Positioning of Therapies in Colorectal Cancer
        • Colorectal Cancer SWOT Analysis
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Colorectal Cancer?
        • What Factors Are Constraining the Market for Colorectal Cancer?
        • Sales of Major Drug Classes, G7 (millions of U.S. dollars): 2020-2030
        • Major-Market Sales of Key Drug Classes by Brand / Biosimilar: 2020-2030
      • Segment-Specific Trends
        • Patient-Share Dynamics of Key Players in Stage III Colon Cancer, United States (2020-2030)
        • Patient-Share Dynamics of Key Players in Stage IV First-Line, Left-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, U.S. (2020-2030)
        • Patient-Share Dynamics of Key Players in Stage IV First-Line, Right-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, U.S. (2020-2030)
        • Patient-Share Dynamics of Key Players in Stage IV First-Line, BRAF Wild-Type, RAS-Mutant Colorectal Cancer, U.S. (2020-2030)
        • Patient-Share Dynamics of Key Players in Stage IV First-Line, BRAF-Mutant, RAS Wild-Type Colorectal Cancer, U.S. (2020-2030)
        • Second-Line Metastatic Colorectal Cancer
        • Patient-Share Dynamics of Key Players in Stage IV Second-Line, Left-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, U.S. (2020-2030)
        • Patient-Share Dynamics of Key Players in Stage IV Second-Line, Right-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, U.S. (2020-2030)
        • Patient-Share Dynamics of Key Players in Stage IV Second-Line, BRAF Wild-Type, RAS-Mutant Colorectal Cancer, U.S. (2020-2030)
        • Patient-Share Dynamics of Key Players in Stage IV Second-Line, BRAF-Mutant, RAS Wild-Type Colorectal Cancer, U.S. (2020-2030)
        • Patient-Share Dynamics of Key Players in Stage IV Third-Line, Left-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, U.S. (2020-2030)
        • Patient-Share Dynamics of Key Players in Stage IV Third-Line, Right-Sided, BRAF Wild-Type, RAS Wild-Type Colorectal Cancer, U.S. (2020-2030)
        • Patient-Share Dynamics of Key Players in Stage IV Third-Line, BRAF Wild-Type, RAS-Mutant Colorectal Cancer, U.S. (2020-2030)
        • Patient-Share Dynamics of Key Players in Stage IV Third-Line, BRAF-Mutant, RAS Wild-Type Colorectal Cancer, U.S. (2020-2030)
    • Forecast
      • Market Forecast Assumptions - Colorectal Cancer
      • Market Forecast Dashboard - Colorectal Cancer
    • Etiology & Pathophysiology
      • Disease Overview
        • Disease Pathophysiology
          • Etiology
          • Risk Factors for Developing Colorectal Cancer
          • Pathophysiology
          • Proposed Adenoma-Carcinoma Sequence Model for Colorectal Cancer With Chromosomal Instability
        • Staging and Classification
          • Staging of Colorectal Cancer
          • TNM Classification of Colorectal Cancer
          • Modified Astler-Coller Dukes Staging System vs. AJCC/UICC Colorectal Cancer (TNM) Staging System
          • Symptoms According to Tumor Location in Colorectal Cancer
          • Screening for Colorectal Cancer
          • Prognostic Factors in Colorectal Cancer
        • Key Pathways and Drug Targets
          • Drug Targets for Colorectal Cancer
          • Select Genes Reportedly Involved in Colorectal Cancer
      • Epidemiology
        • Key Findings
          • Key Updates
        • Epidemiology Populations
          • Disease Definition
          • Methods
          • Sources Used for Diagnosed Incidence of Colorectal Cancer
          • Diagnosed Incident Cases of Colorectal Cancer: 2020-2030
          • Disease Definition
          • Methods
          • Sources Used for Stage Distribution of Colorectal Cancer
          • Diagnosed Incident Cases of Colorectal Cancer by Stage Distribution: 2020-2030
          • Definition
          • Methods
          • Sources Used for Recurrent Incidence of Colorectal Cancer
          • Recurrent Incident Cases of Colorectal Cancer: 2020-2030
          • Colorectal Cancer Patient Flow
          • Drug-Treatable Cases of Colorectal Cancer: 2020-2030
          • Drug-Treated Cases of Colorectal Cancer: 2020-2030
      • Current Treatment
        • Key Findings
          • Treatment Goals
            • Key Endpoints Used in Clinical Trials for Colorectal Cancer
          • Key Current Therapies
            • Overview
            • Mechanism of Action of Key Current Drug Classes Used for Colorectal Cancer
            • Current Treatments Used for Colorectal Cancer
            • Market Events Impacting the Use of Key Current Therapies in Colorectal Cancer
            • Advantages and Disadvantages of Bevacizumab
            • Key Results From Select Clinical Trials Investigating Bevacizumab for the Treatment of Colorectal Cancer
            • Expert Insight: Bevacizumab
            • Advantages and Disadvantages of Zaltrap
            • Key Results From Select Clinical Trials Investigating Zaltrap for the Treatment of Colorectal Cancer
            • Expert Insight: Zaltrap
            • Advantages and Disadvantages of Cyramza
            • Key Results From Select Clinical Trials Investigating Cyramza for the Treatment of Colorectal Cancer
            • Ongoing Clinical Development of Cyramza
            • Key Ongoing Clinical Trials of Cyramza in the Treatment of Colorectal Cancer
            • Expert Insight: Cyramza
            • Advantages and Disadvantages of Stivarga
            • Key Results From Select Clinical Trials Investigating Stivarga for the Treatment of Colorectal Cancer
            • Expert Insight: Stivarga
            • Advantages and Disadvantages of Erbitux
            • Key Results From Select Clinical Trials Investigating Erbitux for the Treatment of Colorectal Cancer
            • Ongoing Clinical Development of Erbitux
            • Key Ongoing Clinical Trials of Erbitux in the Treatment of Colorectal Cancer
            • Expert Insight: Erbitux
            • Advantages and Disadvantages of Vectibix
            • Key Results From Select Clinical Trials Investigating Vectibix for the Treatment of Colorectal Cancer
            • Ongoing Clinical Development of Vectibix
            • Key Ongoing Clinical Trials of Vectibix in the Treatment of Colorectal Cancer
            • Expert Insight: Vectibix
            • Key Results From Select Clinical Trials Investigating Keytruda for the Treatment of Colorectal Cancer
            • Ongoing Clinical Development of Keytruda
            • Key Results From Select Clinical Trials Investigating Opdivo for the Treatment of Colorectal Cancer
            • Ongoing Clinical Development of Opdivo
            • Key Ongoing Clinical Trials of Opdivo in the Treatment of Colorectal Cancer
            • Expert Insight: Opdivo
            • Key Results From Select Clinical Trials Investigating Braftovi for the Treatment of Colorectal Cancer
            • Ongoing Clinical Development of Braftovi
            • Key Ongoing Clinical Trials of Braftovi in the Treatment of Colorectal Cancer
            • Expert Insight: Braftovi
            • Advantages and Disadvantages of Lonsurf
            • Key Results From Select Clinical Trials Investigating Lonsurf for the Treatment of Colorectal Cancer
            • Ongoing Clinical Development of Lonsurf
            • Key Ongoing Clinical Trials of Lonsurf in the Treatment of Colorectal Cancer
            • Expert Insight: Lonsurf
          • Medical Practice
            • Stage II/III Colon Cancer
            • Stage II/III Rectal Cancer
            • Treatment of Colorectal Cancer With Resectable Liver Metastases
            • Second-Line Treatment of Metastatic Colorectal Cancer
            • Third- and Later-Line Treatment of Metastatic Colorectal Cancer
            • Patient Characteristics Influencing Drug Selection in Colorectal Cancer
            • Treatment Decision Tree for Stage II/III Colon and Rectal Cancer: G7
            • Treatment Decision Tree for Stage IV Colorectal Cancer: United States
            • Treatment Decision Tree for Stage IV Colorectal Cancer: France, Germany, Italy, and Spain
            • Treatment Decision Tree for Stage IV Colorectal Cancer: United Kingdom
            • Treatment Decision Tree for Stage IV Colorectal Cancer: Japan
        • Unmet Need Overview
          • Current and Future Attainment of Unmet Needs in Colorectal Cancer
          • Top Unmet Needs in Colorectal Cancer: Current and Future Attainment
          • Expert Insights: Unmet Need in Colorectal Cancer
        • Emerging Therapies
          • Key Findings
            • Key Emerging Therapies
              • Key Therapies in Development for Colorectal Cancer
              • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Colorectal Cancer
              • Key Results From Select Clinical Trials Investigating Fruquintinib for the Treatment of Colorectal Cancer
              • Key Ongoing Clinical Trials of Fruquintinib in the Treatment of Colorectal Cancer
              • Analysis of the Clinical Development Program for Fruquintinib
              • Expert Insight: Fruquintinib
              • Expectations for Market Authorization and Sales Opportunity of Fruquintinib in Colorectal Cancer
              • Key Results From Select Clinical Trials Investigating Lenvima for the Treatment of Colorectal Cancer
              • Key Ongoing Clinical Trials of Lenvima in the Treatment of Colorectal Cancer
              • Analysis of the Clinical Development Program for Lenvima
              • Expert Insight: Lenvima
              • Expectations for Market Authorization and Sales Opportunity of Lenvima in Colorectal Cancer
              • Key Results From Select Clinical Trials Investigating Adagrasib for the Treatment of Colorectal Cancer
              • Key Ongoing Clinical Trials of Adagrasib in the Treatment of Colorectal Cancer
              • Analysis of the Clinical Development Program for Adagrasib
              • Expert Insight: Adagrasib
              • Expectations for Market Authorization and Sales Opportunity of Adagrasib in Colorectal Cancer
              • Key Results From Select Clinical Trials Investigating Tecentriq for the Treatment of Colorectal Cancer
              • Key Ongoing Clinical Trials of Tecentriq in the Treatment of Colorectal Cancer
              • Analysis of the Clinical Development Program for Tecentriq
              • Expert Insight: Tecentriq
              • Expectations for Market Authorization and Sales Opportunity of Tecentriq in Colorectal Cancer
              • Key Ongoing Clinical Trials of Bavencio in the Treatment of Colorectal Cancer
              • Analysis of the Clinical Development Program for Bavencio
              • Expert Insight: Bavencio
              • Expectations for Market Authorization and Sales Opportunity for Bavencio in Colorectal Cancer
              • Key Results From Select Clinical Trials Investigating OncoVAX for the Treatment of Colorectal Cancer
              • Key Ongoing Clinical Trials of OncoVAX in the Treatment of Colorectal Cancer
              • Analysis of the Clinical Development Program for OncoVAX
              • Expert Insight: OncoVAX
              • Expectations for Market Authorization and Sales Opportunity for OncoVAX in Colorectal Cancer
              • Key Results From Select Clinical Trials Investigating Arfolitixorin for the Treatment of Colorectal Cancer
              • Key Ongoing Clinical Trials of Arfolitixorin in the Treatment of Colorectal Cancer
              • Analysis of the Clinical Development Program for Arfolitixorin
              • Expectations for Market Authorization and Sales Opportunity of Arfolitixorin in Colorectal Cancer
              • Key Results From Select Clinical Trials Investigating Lynparza for the Treatment of Colorectal Cancer
              • Key Ongoing Clinical Trials of Lynparza in the Treatment of Colorectal Cancer
              • Analysis of the Clinical Development Program for Lynparza
              • Expert Insight: Lynparza
              • Expectations for Market Authorization and Sales Opportunity of Lynparza in Colorectal Cancer
              • Key Results From Select Clinical Trials Investigating Tukysa for the Treatment of Colorectal Cancer
              • Key Ongoing Clinical Trials of Tukysa in the Treatment of Colorectal Cancer
              • Analysis of the Clinical Development Program for Tukysa
              • Expert Insight: Tukysa
              • Expectations for Market Authorization and Sales Opportunity of Tukysa in Colorectal Cancer
            • Early-Phase Pipeline Analysis
              • Select Compounds in Early-Phase Development for Colorectal Cancer
          • Access & Reimbursement Overview
            • Region-Specific Reimbursement Practices
              • Key Market Access Considerations in Colorectal Cancer: United States
              • General Reimbursement Environment: United States
              • Key Market Access Considerations in Colorectal Cancer: EU5
              • General Reimbursement Environment: EU5
              • Key Market Access Considerations in Colorectal Cancer: Japan
              • General Reimbursement Environment: Japan
          • Appendix
            • Colorectal Cancer Bibliography

        launch Related Market Assessment Reports